Benzinga | Oct 13, 2021 04:55AM EDT

Oppenheimer Initiates Coverage On Jasper Therapeutics with Outperform Rating, Announces Price Target of $21

Oppenheimer analyst Jay Olson initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Outperform rating and announces Price Target of $21.